ATE413883T1 - Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose - Google Patents

Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose

Info

Publication number
ATE413883T1
ATE413883T1 AT02747932T AT02747932T ATE413883T1 AT E413883 T1 ATE413883 T1 AT E413883T1 AT 02747932 T AT02747932 T AT 02747932T AT 02747932 T AT02747932 T AT 02747932T AT E413883 T1 ATE413883 T1 AT E413883T1
Authority
AT
Austria
Prior art keywords
carbon monoxide
tissue
suppresses apoptosis
organ transplantations
improves results
Prior art date
Application number
AT02747932T
Other languages
English (en)
Inventor
Fritz Bach
Edda Tobiasch
Miguel Soares
Leo OTTERBEIN
Jeanne GOSE
Original Assignee
Beth Israel Hospital
Univ Yale
Jeanne GOSE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27404726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE413883(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beth Israel Hospital, Univ Yale, Jeanne GOSE filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE413883T1 publication Critical patent/ATE413883T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02747932T 2001-06-21 2002-06-21 Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose ATE413883T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30028901P 2001-06-21 2001-06-21
US33434001P 2001-11-29 2001-11-29
US33797401P 2001-12-07 2001-12-07

Publications (1)

Publication Number Publication Date
ATE413883T1 true ATE413883T1 (de) 2008-11-15

Family

ID=27404726

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02747932T ATE413883T1 (de) 2001-06-21 2002-06-21 Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose

Country Status (25)

Country Link
US (2) US7238469B2 (de)
EP (2) EP2033514A3 (de)
JP (1) JP4521183B2 (de)
KR (1) KR20040032115A (de)
CN (1) CN100502650C (de)
AT (1) ATE413883T1 (de)
AU (2) AU2002318377B2 (de)
BG (1) BG108492A (de)
BR (1) BR0210599A (de)
CA (1) CA2451266A1 (de)
CY (1) CY1108798T1 (de)
CZ (1) CZ20033448A3 (de)
DE (1) DE60229848D1 (de)
DK (1) DK1404811T3 (de)
ES (1) ES2316583T3 (de)
HU (1) HUP0400371A3 (de)
MX (1) MXPA03012031A (de)
NO (1) NO20035637L (de)
NZ (1) NZ562962A (de)
PL (1) PL367544A1 (de)
PT (1) PT1404811E (de)
SG (1) SG147305A1 (de)
SI (1) SI1404811T1 (de)
SK (1) SK15942003A3 (de)
WO (1) WO2003000114A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
CA2451266A1 (en) * 2001-06-21 2003-01-03 Beth Israel Deaconess Medical Center Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
CA2475209A1 (en) * 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7364757B2 (en) 2002-02-13 2008-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating vascular disease
US7981448B2 (en) * 2002-04-15 2011-07-19 University Of Pittsburgh Methods of treating necrotizing enterocolitis
ES2546280T3 (es) 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
JP2005522521A (ja) 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
PL205066B1 (pl) * 2002-05-17 2010-03-31 Univ Pittsburgh Zastosowanie tlenku węgla do wytwarzania kompozycji farmaceutycznej
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
MXPA04012863A (es) * 2002-06-21 2005-03-31 Univ Pittsburgh Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme.
WO2004043341A2 (en) * 2002-11-07 2004-05-27 University Of Pittsburgh Of The Commonwealth System Of Higher Education Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
EP1689228A2 (de) * 2003-10-22 2006-08-16 Fred Hutchinson Cancer Research Center Verfahren, zusammensetzungen und geräte zur induktion von stasis in zellen
EP1552840A1 (de) * 2004-01-07 2005-07-13 Aga Ab Mischung aus Xenon und Kohlenmonoxyd zum Schutz von Zellen
CA2600927C (en) 2005-03-07 2017-04-18 Sangart, Inc. Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers
EP1937059A2 (de) 2005-07-27 2008-07-02 University Of North Carolina At Charlotte Zusammensetzung und verfahren für die instandsetzung und konservierung von transplantationsorganen von dcd-spendern
WO2007073225A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
EP2099463B1 (de) 2006-11-07 2014-07-16 The General Hospital Corporation Minderung von vasoaktiver sauerstoffträger-induzierter gefässverengung
HUE052999T2 (hu) 2009-05-27 2021-06-28 Mallinckrodt Hospital Products Ip Ltd Eszköz beosztásos szelep és nyomás alatti tartályszerelvény összefogására gallérral és a dugattyú szerelvény által történõ lineáris mûködtetéshez az eszközzel történõ folyadék kommunikációban a gyógyszer-bejuttatás szabályozása érdekében
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
ES2742829T3 (es) 2011-01-14 2020-02-17 Los Angeles Childrens Hospital Solución de monóxido de carbono para el tratamiento de una enfermedad, incluida anemia de células falciformes
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
EP2685815A4 (de) 2011-03-16 2014-09-17 Mayo Foundation Verfahren und materialien zur verlängerung der verwendbarkeit gelagerter erythrozyten- und thrombozyten-präparate
ES2656237T3 (es) 2011-04-19 2018-02-26 Alfama, Inc. Moléculas liberadoras de monóxido de carbono y usos de las mismas
AU2012267620B2 (en) * 2011-06-10 2016-07-07 VERO Biotech LLC. Pressurized Vessel of Nitric Oxide (NO)
EP2734235B1 (de) 2011-07-21 2017-03-22 Alfama, Inc. Kohlenmonoxidfreisetzende rutheniummoleküle und ihre verwendungen
US9987302B2 (en) 2011-08-09 2018-06-05 Beth Israel Deaconess Medical Center, Inc. Methods of treating DNA damage
US9629358B2 (en) 2013-03-15 2017-04-25 Mallinckrodt Hospital Products IP Limited Administration and monitoring of nitric oxide in ex vivo fluids
ES2981406T3 (es) 2013-03-15 2024-10-08 Mallinckrodt Pharmaceuticals Ireland Ltd Administración y monitorización de óxido nítrico en fluidos ex vivo
TW201618795A (zh) 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
WO2017027810A2 (en) 2015-08-12 2017-02-16 The General Hospital Corporation Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
CN105288599A (zh) * 2015-10-22 2016-02-03 徐州医学院 血红素氧化酶-2在制备抑制器官移植免疫排斥制剂中的应用
CN111107742A (zh) * 2017-08-25 2020-05-05 马林克罗特医疗产品知识产权公司 提高器官生存能力的方法
EP3524290A1 (de) 2018-02-09 2019-08-14 Julius-Maximilians-Universitaet Wuerzburg Verfahren und system zur überwachung der kohlenmonoxid(co)-verabreichung an ex-vivo-flüssigkeiten
CN116076484A (zh) * 2022-11-30 2023-05-09 武汉大学 一种修复肾脏损伤的低温携氧机械灌注液及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4053590A (en) * 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4264739A (en) * 1979-01-05 1981-04-28 Merck & Co., Inc. Sparger for cell culture system
JPS5679957A (en) 1979-12-05 1981-06-30 Sogo Seibutsu Igaku Kenkyusho:Kk Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this
US5240912A (en) * 1983-05-09 1993-08-31 Todaro George J Transforming growth factor (TGF) peptides
US5084380A (en) * 1985-01-29 1992-01-28 Applied Biotechnology Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
CN85202057U (zh) * 1985-05-31 1986-09-10 南京低压阀门厂 电热丝预热凹槽式燃油系统
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
DE3739650C1 (de) * 1987-11-23 1989-05-24 Immuno Ag Fermenter zum Zuechten von Zellkulturen
DE3928144A1 (de) * 1989-08-25 1991-02-28 Hoechst Ag Zyklische pyridin-2,4- und -2,5-dicarbonsaeurediamide, verfahren zu deren herstellung sowie deren verwendung
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
US5792325A (en) * 1990-11-15 1998-08-11 Richardson, Jr.; William H. Electric arc material processing system
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
US5396882A (en) 1992-03-11 1995-03-14 The General Hospital Corporation Generation of nitric oxide from air for medical uses
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
WO1994018954A1 (en) * 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
EP0804244A1 (de) * 1993-03-26 1997-11-05 Biorelease Technologies, Inc. Häm-proteine enthaltende zusammensetzungen und dazu gehörende methoden
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells
US6066333A (en) * 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation
US5664563A (en) * 1994-12-09 1997-09-09 Cardiopulmonary Corporation Pneumatic system
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US6063407A (en) 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735382B1 (fr) * 1995-06-15 1997-07-25 Air Liquide Installation de production de monoxyde de carbone incorporant une unite de separation cryogenique
EP0835115B1 (de) * 1995-06-30 2004-05-06 ZymoGenetics, Inc. 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste
EP0914103B1 (de) * 1996-04-05 2006-06-28 The General Hospital Corporation Behandlung einer hämoglobinstörung
US6069132A (en) * 1996-08-14 2000-05-30 Revanker; Ganapathi R. Phosphazole compounds
ES2210585T3 (es) 1996-08-27 2004-07-01 Messer Griesheim Gmbh Medicamento que contiene hidrogeno.
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
DE69737562T2 (de) * 1996-09-27 2007-12-27 The Trustees Of Columbia University In The City Of New York Behandlung einer ischämischen störung und zur verbesserung des infarktergebnis
US5869538A (en) * 1996-11-26 1999-02-09 Research Foundation Of State University Of New York Method for enhancing transport of gases to tissues
FR2757259B1 (fr) * 1996-12-18 1999-03-05 Valeo Thermique Moteur Sa Ailette metallique perfectionnee pour echangeur de chaleur, notamment pour vehicule automobile
US5912019A (en) * 1997-02-07 1999-06-15 Musc Foundation For Research Development Compounds for reducing ischemia/reperfusion injury
ES2243052T3 (es) 1998-03-16 2005-11-16 Celgene Corporation Derivados de la 2- (2,6-dioxopiperidin-3-il) isoindolina, su preparacion y su empleo como inhibidores de las citocinas inflamatorias.
US6203991B1 (en) * 1998-08-21 2001-03-20 The Regents Of The University Of Michigan Inhibition of smooth muscle cell migration by heme oxygenase I
US20050250688A1 (en) * 1999-04-01 2005-11-10 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7632803B2 (en) * 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US6558825B1 (en) * 2000-05-12 2003-05-06 Reveo, Inc. Fuel containment and recycling system
FR2812197B1 (fr) 2000-07-27 2003-01-03 Air Liquide Sante Int Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
FR2816212A1 (fr) 2000-11-03 2002-05-10 Air Liquide Sante Int Utilisation de monoxyde de carbone (co) dans le traitement des inflammations du systeme cardiovasculaire
WO2002080859A2 (en) * 2001-03-20 2002-10-17 Glaxo Group Limited Inhalation drug combinations
IL158182A0 (en) * 2001-03-30 2004-03-28 Sangstat Medical Corp Carbon monoxide generating compounds for treatment of vacular, inflammatory and immune disorders
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1395241B9 (de) * 2001-05-25 2005-06-15 Medtronic, Inc. Implantierbare medizinische vorrichtung mit kontrollierter freigabe von gasförmigen mitteln
CA2451266A1 (en) * 2001-06-21 2003-01-03 Beth Israel Deaconess Medical Center Inc. Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
CA2475209A1 (en) * 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
US7364757B2 (en) * 2002-02-13 2008-04-29 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating vascular disease
JP2005522521A (ja) * 2002-04-15 2005-07-28 ベス イスラエル デアコネス メディカル センター ヘムオキシゲナーゼ−１およびヘム分解産物の使用法
ES2546280T3 (es) * 2002-04-15 2015-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monóxido de carbono para su uso en un método para tratar íleo
US7981448B2 (en) * 2002-04-15 2011-07-19 University Of Pittsburgh Methods of treating necrotizing enterocolitis
PL205066B1 (pl) * 2002-05-17 2010-03-31 Univ Pittsburgh Zastosowanie tlenku węgla do wytwarzania kompozycji farmaceutycznej
EA200401622A1 (ru) * 2002-06-05 2005-06-30 Йейл Юниверсити Способы лечения ангиогенеза, роста опухолей и метастазов
MXPA04012863A (es) * 2002-06-21 2005-03-31 Univ Pittsburgh Uso farmaceutico de oxido nitrico, heme oxigenasa-1 y productos de degradacion de heme.
WO2004043341A2 (en) * 2002-11-07 2004-05-27 University Of Pittsburgh Of The Commonwealth System Of Higher Education Treatment for hemorrhagic shock
WO2005077005A2 (en) * 2004-02-04 2005-08-25 The General Hospital Corporation Enhancing the effectiveness of an inhaled therapeutic gas

Also Published As

Publication number Publication date
US20030039638A1 (en) 2003-02-27
DK1404811T3 (da) 2009-03-02
WO2003000114A2 (en) 2003-01-03
JP2005500875A (ja) 2005-01-13
EP2033514A3 (de) 2009-04-29
CN100502650C (zh) 2009-06-24
SI1404811T1 (sl) 2009-04-30
US20070202083A1 (en) 2007-08-30
EP1404811B1 (de) 2008-11-12
US7238469B2 (en) 2007-07-03
EP1404811A2 (de) 2004-04-07
BG108492A (bg) 2005-02-28
AU2002318377B2 (en) 2008-06-19
BR0210599A (pt) 2004-07-20
CZ20033448A3 (cs) 2004-05-12
WO2003000114A9 (en) 2004-05-21
EP1404811A4 (de) 2006-08-09
JP4521183B2 (ja) 2010-08-11
DE60229848D1 (de) 2008-12-24
PT1404811E (pt) 2009-01-22
NO20035637L (no) 2004-02-17
SK15942003A3 (sk) 2004-08-03
AU2008221551A1 (en) 2008-10-09
NZ562962A (en) 2009-08-28
HK1067380A1 (en) 2005-04-08
ES2316583T3 (es) 2009-04-16
CN1545548A (zh) 2004-11-10
SG147305A1 (en) 2008-11-28
HUP0400371A2 (hu) 2004-08-30
KR20040032115A (ko) 2004-04-14
WO2003000114A3 (en) 2003-04-10
NO20035637D0 (no) 2003-12-17
EP2033514A2 (de) 2009-03-11
CA2451266A1 (en) 2003-01-03
PL367544A1 (en) 2005-02-21
HUP0400371A3 (en) 2010-06-28
CY1108798T1 (el) 2014-04-09
MXPA03012031A (es) 2005-07-01

Similar Documents

Publication Publication Date Title
ATE413883T1 (de) Kohlenmonoxid verbessert die ergebnisse bei gewebe- und organtransplantationen und unterdrückt apoptose
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
WO2004009767A3 (en) Cell therapy for regeneration
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
WO2003040346A3 (en) Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
DE69941903D1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
BRPI0410185A (pt) composição para manter a viabilidade de um orgão e célula
AU2002345991A1 (en) Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ
GB2434157A (en) Platelets from stem cells
EP2465921A3 (de) Herzstammzellen aus der Biopsie
EP1414996A4 (de) Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen
PT2163614T (pt) Animais porcinos que carecem de qualquer expressão de alfa 1,3 galactosiltransferase funcional
ECSP066422A (es) Método para obtener factores citotóxicos provenientes de microorganismos, factores citotóxicos obtenidos y composición farmacéutica y conjunto que los contienen.
WO2003012060A3 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
WO2007025215A3 (en) Machine perfusion of tissue grafts for transplantation
DK1274464T3 (da) Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
EP2216033A3 (de) Behandlungsmethode einer Erkrankung durch Transplantation eines allogenen oder xenogenen Organs oder Gewebe
EP2527427A3 (de) Multipotente Postnatale Stammzellen aus dem humanen periodontalen Ligament und deren Verwendung
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
WO2003078607A3 (en) Tissue specific signal-plexes to dedifferentiate and redifferentiate cells
IL190289A0 (en) Method for obtaining human smooth muscular cells and uses thereof
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
DE60043888D1 (de) Oberfläche für zellkultur
WO2024077153A8 (en) Pluripotent stem cell-derived megakaryocytes and platelets

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1404811

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked